Latest News on SUPN

Financial News Based On Company


Advertisement
Advertisement

Piper Sandler Resumes Supernus Coverage With Overweight Rating

https://www.tokenpost.com/news/investing/49234
Piper Sandler has resumed coverage of Supernus Pharmaceuticals (SUPN) with an Overweight rating and a $47 price target. The firm's positive outlook is tied to Supernus's announced merger with Indivior, which is expected to enhance the combined company's capacity for business development and acquisitions. This merger aims to create a stronger entity than what either company could achieve individually.

Form 4 Supernus, Inc: Carrolee Barlow (Director) For: 2 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-supernus-inc-carrolee-barlow-director-for-2-november-93CH-4959180
This article reports on a Form 4 filing for Supernus, Inc., indicating an insider transaction by Director Carrolee Barlow on November 2nd. The brief notice, published by Investing.com, provides no further details on the nature or value of the transaction.

Only fractional-share cash accompanies a Supernus (SUPN) director’s 124,119-share merger exchange.

https://www.stocktitan.net/sec-filings/SUPN/form-4-supernus-pharmaceuticals-inc-insider-trading-activity-b7b3f00ca45b.html
Supernus Pharmaceuticals, Inc. director Charles W. Newhall III reported the disposal of 124,119 common shares in a November 2, 2026 merger. These shares were converted into the right to receive 1.5401 shares of Indivior common stock per Supernus share, with Newhall receiving only cash in lieu of a fractional share. The merger also involved the conversion of Newhall's restricted stock units and stock options into corresponding awards under the new entity, Supernus, Inc.

Supernus (SUPN) director Hudson disposed of 60,413 shares

https://www.quantisnow.com/insight/director-hudson-frederick-m-disposed-of-60413-shares-closing-all-6773009
Frederick M. Hudson, a director at Supernus Inc. (SUPN), reported the disposition of 60,413 shares on November 2, 2026, as part of a merger agreement with Indivior Pharmaceuticals, Inc. These shares were converted into Indivior stock at a 1.5401 ratio, not through an open-market sale. After these transactions, Hudson directly holds 0 shares of Supernus.

Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued

https://sg.finance.yahoo.com/news/supernus-pharmaceuticals-supn-indivior-merger-141813995.html
Supernus Pharmaceuticals (SUPN) recently completed an all-stock merger with Indivior Pharmaceuticals, forming Supernus, Inc. Despite a recent share price decline over 90 days and a year, the company's 3-year total shareholder return is significantly up, and it is currently seen by many as undervalued, trading at $41.92 against a fair value of $61.75. The combined entity is expected to generate approximately $2.2 billion in pro forma revenue and $888 million in adjusted EBITDA, though risks include integration challenges and cash obligations.
Advertisement

Form 4 Supernus, Inc: Frank Mottola (SVP, Chief Tech. Ops. Officer) For: 2 November

https://ca.investing.com/news/stock-market-news/form-4-supernus-inc-frank-mottola-svp-chief-tech-ops-officer-for-2-november-93CH-4932649
This article reports on a Form 4 filing for Supernus, Inc., indicating a transaction involving Frank Mottola, the SVP and Chief Technology Operations Officer, for November 2nd. Form 4 filings are required by the SEC when there's a change in ownership of company stock by an insider. The brief article, published by Investing.com, serves as a direct notification of this regulatory event.

Form 4 SUPERNUS PHARMACEUTICALS: Padmanabh P. Bhatt (Sr. VP of IP, CSO) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-supernus-pharmaceuticals-padmanabh-p-bhatt-sr-vp-of-ip-cso-for-30-october-93CH-4924366
This article reports a Form 4 filing for Supernus Pharmaceuticals concerning Padmanabh P. Bhatt, the Senior VP of IP and CSO, for activity on October 30. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's insiders. The content of the filing itself is not detailed, but the article provides the context of the insider transaction.

Supernus and Indivior complete merger to form 11-product CNS company

https://allsci.com/news/m-a/supernus-indivior-merger-pharmaceuticals-and/
Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, forming Supernus, Inc. with an 11-product central nervous system (CNS) portfolio. The new company, trading as SUPN on Nasdaq, aims to leverage its enhanced financial capacity for commercial growth and pipeline advancement. The merger involved Supernus stockholders receiving Indivior shares and Indivior stockholders a $1.0 billion special cash dividend.

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

https://www.globenewswire.com/news-release/2026/11/02/3393272/19871/en/supernus-and-indivior-complete-merger-creating-a-diversified-cns-biopharmaceutical-leader.html
Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have completed their merger, officially forming Supernus, Inc., a diversified biopharmaceutical company focused on central nervous system (CNS) diseases. This merger positions Supernus as a leader in the CNS biopharmaceutical space with an expanded 11-product portfolio, enhanced financial flexibility, and a differentiated pipeline. The combined entity will trade on the Nasdaq Global Market under the ticker symbol "SUPN" starting November 3, 2026.

Form 4 Supernus Pharmaceuticals Inc: Jack A. Khattar (Director, President, CEO) For: 30 October

https://uk.investing.com/news/stock-market-news/form-4-supernus-pharmaceuticals-inc-jack-a-khattar-director-president-ceo-for-30-october-93CH-4950559
This article reports on a Form 4 filing for Supernus Pharmaceuticals Inc., specifically detailing a transaction by Jack A. Khattar, who serves as Director, President, and CEO. The filing is related to activity on October 30th.
Advertisement

Supernus and Indivior Complete Merger, Creating Diversified CNS Biopharmaceutical Company

https://www.citybiz.co/article/927523/supernus-and-indivior-complete-merger-creating-diversified-cns-biopharmaceutical-company/
Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, forming Supernus, Inc. (Nasdaq: SUPN), a diversified biopharmaceutical company with an 11-product commercial portfolio in opioid use disorder, psychiatry, and neurology. The merger combines Supernus’ neurology and psychiatry treatments with Indivior’s addiction medicine business, expanding the combined company’s commercial scale and financial resources. Jack Khattar will lead the new company, which aims to improve cash generation and support further product commercialization and development.

Nasdaq submits a listing and/or registration removal notice for Supernus (NASDAQ: SUPN) common stock.

https://www.stocktitan.net/sec-filings/SUPN/25-nse-supernus-pharmaceuticals-inc-sec-filing-8bfcc329b8a6.html
The Nasdaq Stock Market LLC has filed a Form 25 notification for the removal of Supernus Pharmaceuticals, Inc. (SUPN) common stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This action indicates Nasdaq believes it has reasonable grounds to meet the requirements for filing this notification. Delisting can lead to reduced visibility, lower trading volume, and wider price swings for investors.

Supernus Secures $650 Million Senior Secured Term Loan for Merger and Refinancing

https://www.tradingview.com/news/tradingview:d9548acc75fc9:0-supernus-secures-650-million-senior-secured-term-loan-for-merger-and-refinancing/
Supernus Pharmaceuticals and its subsidiaries entered into a $650 million senior secured term loan agreement with Citibank and other lenders on November 2, 2026. The full amount was borrowed at closing, with proceeds intended to fund a merger, refinance existing debt, cover transaction costs, and support general corporate purposes. Interest rates are based on Term SOFR or the Base Rate plus an applicable margin, which will vary based on leverage after the initial period.

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

https://ca.finance.yahoo.com/news/supernus-indivior-complete-merger-creating-141800388.html
Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have successfully completed their merger, creating Supernus, Inc., a diversified biopharmaceutical company focused on central nervous system (CNS) diseases. This merger positions Supernus as a leader with an 11-product portfolio, enhanced financial flexibility, and a differentiated pipeline, aimed at expanding treatments for patients and delivering long-term shareholder value. The combined entity will trade on the Nasdaq Global Market under the ticker symbol "SUPN" starting November 3, 2026.

Press Release: Supernus Announces Third Quarter 2026 Financial Results

https://www.moomoo.com/news/post/1002879184/press-release-supernus-announces-third-quarter-2026-financial-results
This press release from Supernus Pharmaceuticals announces its financial results for the third quarter of 2026. The company reported its earnings, revenue, and other key financial metrics for the period. Further details would be found within the full document of the press release.
Advertisement

Four treatments brought in $192.2 million for Supernus, up 29%.

https://www.stocktitan.net/news/SUPN/supernus-announces-third-quarter-2026-financial-b2u2mwfl7mgk.html
Supernus Pharmaceuticals (SUPN) announced strong third-quarter 2026 financial results, with total revenue rising 18% to $226.8 million and combined revenue from its four growth products increasing 29% to $192.2 million. The company returned to quarterly profitability, reporting net earnings of $20.9 million, and raised its stand-alone 2026 revenue guidance. Supernus also confirmed that its all-stock merger with Indivior is expected to close on November 2, 2026, anticipating $125 million in annual cost synergies.

Supernus Pharmaceuticals Reports $20.9M Net Profit in Q3 2026 Amid Revenue Growth

https://kalkinemedia.com/us/news/announcements/supernus-pharmaceuticals-reports-209m-net-profit-in-q3-2026-amid-revenue-growth
Supernus Pharmaceuticals, Inc. reported a net profit of $20.9 million in Q3 2026, a significant turnaround from a net loss in the prior year's comparable quarter. The company's total revenues increased to $226.8 million, driven by strong product sales and growth in collaboration revenue from ZURZUVAE. Despite a year-to-date net loss of $39.8 million due to impairment charges, the quarterly performance highlights a return to profitability and solid revenue growth.

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62723016/supernus-pharmaceuticals-q3-2026-earnings-call-transcript
Supernus Pharmaceuticals reported a strong third quarter in 2026, with total revenue increasing 18% year-over-year to $226.8 million, driven by growth products like Qelbree, Zurzuvae, Onapco, and Gocovri. The company raised its full-year 2026 revenue guidance to $875 million – $900 million and non-GAAP operating earnings to $160 million – $180 million. The merger with Indivior Pharmaceuticals is expected to close on November 2nd, creating a combined entity with significant earnings and cash flow potential, and aiming for $125 million in annual cost synergies.

Form 8K Supernus Pharmaceuticals Inc For: 29 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-supernus-pharmaceuticals-inc-for-29-october-93CH-2768859
This article reports on Supernus Pharmaceuticals Inc.'s Form 8K filing for October 29. The filing, available on Investing.com, indicates a corporate event or significant development for the company. The article includes the stock symbol SUPN and a slight positive change for the day.

Supernus: Q3 Earnings Snapshot

https://www.10tv.com/article/syndication/associatedpress/supernus-q3-earnings-snapshot/616-6b029de7-5f5f-49b1-9e58-a52ea6ac421f
Supernus Pharmaceuticals Inc. reported a Q3 profit of $20.9 million, equating to 35 cents per share. After adjustments for amortization and stock option expenses, earnings reached 93 cents per share. The drugmaker also announced revenues of $226.8 million for the same period.
Advertisement

Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic

https://www.tradingview.com/news/stockstory:55bcae110094b:0-supernus-pharmaceuticals-nasdaq-supn-delivers-impressive-q3-2026-full-year-sales-guidance-is-optimistic/
Supernus Pharmaceuticals (NASDAQ:SUPN) reported impressive Q3 2026 results, surpassing Wall Street's revenue and EPS expectations with revenue up 18.1% year-on-year to $226.8 million and GAAP profit of $0.35 per share. The company also raised its full-year revenue guidance to $887.5 million, reflecting continued momentum across its commercial portfolio. Following the results, Supernus Pharmaceuticals is looking forward to closing its merger with Indivior to create a diverse CNS biopharmaceutical leader.

Form 8K Supernus Pharmaceuticals Inc For: 29 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-supernus-pharmaceuticals-inc-for-29-october-93CH-4915272
This article from Investing.com announces the filing of a Form 8K by Supernus Pharmaceuticals Inc. for October 29. The brief report highlights the event with the company's stock symbol SUPN and includes a Reuters image. The content is primarily a notification rather than an in-depth analysis of the Form 8K filing.

Supernus expands Ms. Represented campaign with help from Olympian Chloe Kim

https://www.mmm-online.com/news/supernus-ms-represented-campaign-olympian-chloe-kim/
Supernus Pharmaceuticals is expanding its "Ms. Represented" campaign by partnering with Olympic snowboarder Chloe Kim to reach a younger, Gen Z audience on social media platforms like TikTok. The campaign aims to combat misinformation about ADHD and its treatments by sharing Kim's personal journey with ADHD and her experience with Supernus's non-stimulant medication, Qelbree. Supernus hopes to provide authentic, fact-based content to empower women who may have been undiagnosed or misdiagnosed with ADHD.

Supernus Announces Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/10/29/3391818/19871/en/supernus-announces-third-quarter-2026-financial-results.html
Supernus Pharmaceuticals, Inc. reported record total revenues of $226.8 million in the third quarter of 2026, an 18% increase year-over-year, driven by strong growth in its four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company also announced the expected closing of its merger with Indivior Pharmaceuticals, Inc. on November 2, 2026, aiming to create a diversified CNS biopharmaceutical leader. Supernus is raising its full-year 2026 financial guidance as a standalone company.

Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign

https://www.globenewswire.com/news-release/2026/10/28/3390176/19871/en/chloe-kim-is-changing-the-conversation-around-adhd-in-women-with-qelbree-for-ms-represented-campaign.html
Professional snowboarder Chloe Kim is partnering with Supernus Pharmaceuticals' 'Ms. Represented' campaign for Qelbree, a non-stimulant ADHD medication. Kim, diagnosed with ADHD as an adult, is sharing her personal journey to challenge narrow perceptions of ADHD and help other women feel understood. The campaign aims to raise awareness about ADHD in women, who are often diagnosed later in life and may exhibit less visible inattentive symptoms.
Advertisement

Supernus Pharmaceuticals Ends UBS Credit Line Ahead of Indivior Combination

https://www.tradingview.com/news/tradingview:14081b963325c:0-supernus-pharmaceuticals-ends-ubs-credit-line-ahead-of-indivior-combination/
Supernus Pharmaceuticals terminated its uncommitted, demand revolving credit line with UBS Bank USA on October 20, 2026. This action was taken in anticipation of its planned business combination with Indivior and the new senior secured credit facility for the combined company. No borrowings were outstanding, and no early termination penalties applied.

Form 8K Supernus Pharmaceuticals Inc For: 26 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-supernus-pharmaceuticals-inc-for-26-october-93CH-4904016
This article announces that Supernus Pharmaceuticals Inc. has filed a Form 8K for October 26. The Form 8K is a crucial document that public companies file with the SEC to announce major events that shareholders should know about. No specific details of the filing are provided in this brief announcement, encouraging readers to view the full document.

Supernus Pharmaceuticals ends UBS credit line ahead of Indivior merger

https://www.investing.com/news/sec-filings/supernus-pharmaceuticals-ends-ubs-credit-line-ahead-of-indivior-merger-93CH-4973717
Supernus Pharmaceuticals has terminated its UBS Credit Line Agreement, effective October 20, 2026, in anticipation of its merger with Indivior Pharmaceuticals. The company stated that no outstanding balances or penalties were incurred, and the combined entity plans to establish a new senior secured credit facility upon the transaction's closing. This move follows Supernus's mixed second-quarter results and the broader trend of increased biotech funding.

Supernus Pharmaceuticals, Inc. Estimates – NASDAQ:SUPN

https://www.tradingview.com/symbols/NASDAQ-SUPN/financials-estimates/
This article from TradingView provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) financial data and analyst estimates. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The page includes sections for income statement, balance sheet, and cash flow, along with a disclaimer about investment advice.

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

https://finance.yahoo.com/markets/stocks/articles/earnings-preview-supernus-pharmaceuticals-supn-130016340.html
Supernus Pharmaceuticals (SUPN) is projected to report a year-over-year decline in Q3 earnings despite higher revenues, with an estimated EPS of $0.49 per share. The stock currently holds a Zacks Rank #5 and an Earnings ESP of 0%, making it difficult to confidently predict an earnings beat. Investors should monitor other factors ahead of the earnings release, expected on October 29.
Advertisement

Form 8K Supernus Pharmaceuticals Inc For: 22 October By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-supernus-pharmaceuticals-inc-for-22-october-93CH-5647490
This article announces that Supernus Pharmaceuticals Inc. filed a Form 8K on October 22. The filing is likely related to significant events that shareholders should be aware of, as per SEC regulations.

Form 8K Supernus Pharmaceuticals Inc For: 22 October By Investing.com

https://au.investing.com/news/stock-market-news/form-8k-supernus-pharmaceuticals-inc-for-22-october-93CH-4707114
This article announces the filing of a Form 8K by Supernus Pharmaceuticals Inc on October 22, 2026. The brief news item indicates a corporate filing for the company, without providing specific details about the contents of the 8K report.

TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65

https://www.moomoo.com/news/post/1001877784/td-cowen-maintains-supernus-pharmaceuticals-supnus-with-buy-rating-maintains
TD Cowen has reiterated its Buy rating for Supernus Pharmaceuticals (SUPN.US), maintaining a target price of $65. This indicates continued confidence in the company's stock performance and future outlook from the investment bank.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

https://www.globenewswire.com/news-release/2026/10/21/3385989/19871/en/supernus-announces-orphan-drug-exclusivity-for-onapgo-apomorphine-hcl.html
Supernus, Inc. announced that the FDA has granted seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for treating motor fluctuations in adults with advanced Parkinson’s disease. This designation provides market exclusivity for ONAPGO, which is the first and only subcutaneous apomorphine infusion device for this condition, starting from its FDA approval date of February 3, 2025. The company also submitted a supplemental New Drug Application for a second supplier, with potential approval by mid-2027, to ensure an uninterrupted drug supply.

Supernus Pharmaceuticals Jumps 5.7% Amid Sector-Wide Rally

https://news.alphastreet.com/supernus-pharmaceuticals-jumps-5-7-amid-sector-wide-rally/
Supernus Pharmaceuticals (NASDAQ:SUPN) saw its stock surge by 5.7% on October 19, 2026, closing at $40.04 as part of a broader rally in the specialty pharmaceutical sector. The $2.3 billion drugmaker's gains were not attributed to company-specific news but rather a coordinated upswing across its peers, driven by macroeconomic factors or shifting investor sentiment. Investors are advised to monitor ongoing sector momentum and policy developments as the stock's future performance is likely tied to broader industry trends rather than individual catalysts.
Advertisement

Supernus Pharmaceuticals Sets October 29 Call for Third Quarter 2026 Results

https://www.quiverquant.com/news/Supernus+Pharmaceuticals+Sets+October+29+Call+for+Third+Quarter+2026+Results
Supernus Pharmaceuticals (SUPN) announced it will release its third-quarter 2026 financial results after market close on October 29, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec. The article also details recent hedge fund activity in SUPN stock, noting significant additions and removals by various institutional investors.

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

https://www.manilatimes.net/2026/10/19/tmt-newswire/globenewswire/supernus-pharmaceuticals-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-october-29-2026/2448736/amp
Supernus Pharmaceuticals, Inc. announced that it will report its third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, which will be accessible via the company's investor relations website.

Supernus Pharmaceuticals Jumps 5.7% Amid Sector-Wide Rally

https://news.alphastreet.com/supernus-pharmaceuticals-jumps-5-7-amid-sector-wide-rally/amp/
Supernus Pharmaceuticals (NASDAQ:SUPN) saw its stock jump 5.7% to $40.04 on Monday, October 19, 2026, as part of a broad rally among specialty pharmaceutical companies. The sector-wide surge, which also saw gains for MBX, VRNO.NE, and TRLV, was driven by macro factors affecting the subsector rather than company-specific news. Investors are now watching to see if this momentum will continue, as Supernus's performance remains tied to overall sector sentiment without an individual catalyst.

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

https://www.globenewswire.com/news-release/2026/10/19/3383428/19871/en/supernus-pharmaceuticals-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-october-29-2026.html
Supernus Pharmaceuticals, Inc. announced that it will report its third quarter 2026 financial and business results after market close on Thursday, October 29, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, featuring President and CEO Jack Khattar and SVP and CFO Tim Dec. A live webcast and replay will be available on the company's investor relations website.

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

https://www.globenewswire.com/news-release/2026/10/19/3383428/0/en/supernus-pharmaceuticals-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-october-29-2026.html
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced it will report its third quarter 2026 financial and business results after market close on Thursday, October 29, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, featuring President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec. A live webcast and replay will be available on the company's Investor Relations website.
Advertisement

Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts

https://au.finance.yahoo.com/research/reports/ARGUS_4670_QuantitativeReport_1791936000000
Argus has lowered its price target for Supernus Pharmaceuticals Inc. (SUPN) to $40.00. Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system diseases. The current stock price is $39.84.

Is Supernus Pharmaceuticals (SUPN) Still Worth A Look After Its Valuation Reset?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/is-supernus-pharmaceuticals-supn-still-worth-a-look-after-it
Supernus Pharmaceuticals (SUPN) has experienced a valuation reset with declining short-term share prices, but remains positive for longer-term holders. While a recent report highlighted unexciting sales and tighter cash flow, the stock is considered 35% undervalued by many, with a fair value of $61.75 compared to its current price of $40.18. The company's valuation debate centers on whether its CNS portfolio's potential is fully reflected, alongside the need for successful merger synergies and revenue growth beyond past averages.

Indivior Shareholders Approve Proposed Merger with Supernus

https://www.indivior.com/latest/category/company-statements/2026/indivior-shareholders-approve-proposed-merger-with-supernus
Indivior's shareholders have approved an all-stock merger of equals with Supernus Pharmaceuticals, Inc., with 94% of votes cast in favor. This transaction, announced in August 2026, is expected to close on November 2, 2026. The combined entity will operate as Supernus, Inc., trading on Nasdaq under "SUPN", aiming to create a diversified CNS-focused biopharmaceutical company.

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4670_QuantitativeReport_1791936000000
Argus has lowered its target price for Supernus Pharmaceuticals, Inc. (SUPN) to $40.00. The company is a specialty pharmaceutical firm focused on developing and commercializing treatments for central nervous system diseases. The current price of SUPN is $40.48.

Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD By Investing.com

https://za.investing.com/news/stock-market-news/supernus-pharmaceuticals-stock-hits-52week-low-at-405-usd-93CH-4504976
Supernus Pharmaceuticals stock dropped to a 52-week low of $40.5, just above its absolute low of $40.51, representing a 16.83% decline over the past year. Despite this, analysts are optimistic with price targets up to $67. The company recently reported mixed Q2 earnings, but a merger with Indivior Pharmaceuticals and increased biotech funding suggest potential for future growth.
Advertisement

Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD

https://www.investing.com/news/company-news/supernus-pharmaceuticals-stock-hits-52week-low-at-405-usd-93CH-4949900
Supernus Pharmaceuticals stock recently hit a 52-week low of $40.5 USD, just above its absolute low of $40.51, representing a 16.83% decline over the past year. Despite this, analysts project a potential upside of up to 65% with price targets between $55 and $67. The company recently reported mixed Q2 earnings but announced a significant merger with Indivior Pharmaceuticals, which is expected to create a large CNS-focused drugmaker, leading to a stock surge despite the earnings miss.

Liquidity Mapping Around (SUPN) Price Events

https://news.stocktradersdaily.com/news_release/20/Liquidity_Mapping_Around_SUPN_Price_Events_101426100201_1791986521.html
This article provides a liquidity mapping analysis for Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating stable neutral readings in shorter horizons which could signal an easing of a long-term weak bias. It highlights an exceptional 31.8:1 risk-reward setup, targeting a 9.3% gain versus 0.3% risk. The analysis includes institutional trading strategies for different risk profiles, multi-timeframe signal analysis, and AI-generated support and resistance levels.

How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f
Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a Parkinson's disease treatment, enhancing its central nervous system portfolio and potentially improving its earning power and product diversity. The approval could streamline sales efforts by adding to Supernus's existing Parkinson's products, with the company projecting significant revenue and earnings growth by 2029. However, the investment narrative hinges on successful prescription and reimbursement uptake, as integration costs and R&D spend could pressure profitability if sales disappoint.

Indivior, Supernus advance merger amid disclosure updates

https://www.theglobeandmail.com/investing/markets/stocks/INDV-Q/pressreleases/5003133/indivior-supernus-advance-merger-amid-disclosure-updates/
Indivior and Supernus Pharmaceuticals are moving forward with their merger plans, despite two lawsuits filed in New York alleging inadequate disclosures. To avoid litigation delays, the companies have voluntarily updated their joint proxy materials with additional valuation-related disclosures. The merger, which will see Supernus survive as a wholly owned unit and the combined company renamed Supernus, Inc., is scheduled for shareholder votes on October 15, 2026.

Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4670_QuantitativeReport_1790726400000
The article attempts to provide stock forecasts for Supernus Pharmaceuticals, Inc. (SUPN) but encounters an error during data retrieval. It primarily displays various market indices, currency exchange rates, and commodity prices, indicating a problem in fetching the specific stock forecast content.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement